

Open Peer Review on Qeios

Anti-AMHR2 Monoclonal Antibody GM102

National Cancer Institute

Source

National Cancer Institute. <u>Anti-AMHR2 Monoclonal Antibody GM102</u>. NCI Thesaurus. Code C136985.

An engineered, humanized, low fucose monoclonal antibody against mullerian hormone receptor II (Müllerian Inhibiting Substance Receptor II; AMHR2; AMHRII), with potential antineoplastic activity. Upon administration, anti-AMHR2 monoclonal antibody GM102 targets, binds to and inhibits AMHR2 and its downstream signaling pathways. GM102 primarily induces antibody dependent cellular cytotoxicity (ADCC) directed against AMHR2-expressing tumor cells through binding to CD16 (Fc-gammaRIIIa) that is present on immune effector cells. Decreased antibody fucosylation increases its affinity for binding to CD16 and ultimately enhances ADCC. AMHR2 is expressed in a subset of gynecological cancers.

Qeios ID: RMXCSY · https://doi.org/10.32388/RMXCSY